Stage T1c prostate cancer: A heterogeneous category with widely varying prognosis

Cancer Journal

Volumn 8, Issue 6, 2002, Pages 440-444

  Hung, Arthur Y ^a   Levy, Larry ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Prostate cancer; Radiation dose; Radiation therapy; Stage T1c

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; STATISTICAL ANALYSIS; SURVIVAL RATE; UNIVARIATE ANALYSIS; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0036835976     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200211000-00007     Document Type: Article

References (14)

1. American Joint Committee on Cancer, American Cancer Society, American College of Surgeons. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
2. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-3911.
3. Asbell SO, Krall JM, Pilepich MV et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-1316.
4. Asbell SO, Martz KL, Shin KH et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998;40:769-782.
5. Zagars GK, von Eschenbach AC, Johnson DE et al. Stage C adenocarcinoma of the prostate: an analysis of 551 patients treated with external beam radiation. Cancer 1987;60:1489-1499.
6. Feneley MR, Landis P, Simon I et al. Today men with prostate cancer have larger prostates. Urology 2000;56:839-842.
7. Jhaveri FM, Klein EA, Kupelian PA et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999;17:3167-3172.
8. Lee AK, Schultz D, Renshaw AA et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 2001;49:673-637.
9. Hintz BL, Murphy JS, Kaswick JA et al. Assessment of relative tumor burden in patients with clinical T1c prostate cancer treated with either external beam or radical prostatectomy. Am J Clin Oncol 1999;22:332-337.
10. Ogawa O, Egawa S, Arai Y et al. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer. Int J Urol 1998;5:454-458.
11. Horwitz EM, Hanlon AL, Pinover WH et al. Defining the optimal radiation dosewith three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 2001;92:1281-1287.
12. Kupelian PA, Buchsbaum JC, Reddy CA et al. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason ≤6, and pretreatment prostate-specific antigen ≤10). Int J Radiat Oncol Biol Phys 2001;50:621-625.
13. Lyons JA, Kupelian PA, Mohan DS et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000;55:85-90.
14. Zelefsky MJ, Fuks Z, Hunt M et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.